Phosphonate Compounds
First Claim
Patent Images
1. An antiviral nucleoside compound having the structure of Formula I:
- wherein;
R1 is —
O—
(CH2)t—
CH3, wherein t is 11 to 19;
a is 2 to 4;
B is hydrogen, —
CH3, or —
CH2OH, Z is and the symbol * indicates that -*CH2—
in Formula I is attached to Z via N* in Formula A or B;
or a pharmaceutically acceptable salt thereof.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.
-
Citations
23 Claims
-
1. An antiviral nucleoside compound having the structure of Formula I:
-
wherein; R1 is —
O—
(CH2)t—
CH3, wherein t is 11 to 19;a is 2 to 4; B is hydrogen, —
CH3, or —
CH2OH,Z is and the symbol * indicates that -*CH2—
in Formula I is attached to Z via N* in Formula A or B;or a pharmaceutically acceptable salt thereof. - View Dependent Claims (2, 3, 4, 5, 6)
or a pharmaceutically acceptable salt thereof.
-
-
7. A pharmaceutical composition comprising an effective amount of an antiviral nucleoside compound of Formula I
wherein: -
R1 is —
O—
(CH2)—
CH3, wherein t is 11 to 19;a is 2 to 4; B is hydrogen, —
CH3, or —
CH2OH, Z isand the symbol * indicates that -*CH2—
in Formula I is attached to Z via N* in Formula A or B,or a pharmaceutically acceptable salt thereof; in combination with a pharmaceutically acceptable carrier. - View Dependent Claims (8, 9, 10)
or a pharmaceutically acceptable salt thereof.
-
-
11. A method for the treatment of a viral disease comprising administering an effective amount of an antiviral nucleoside compound of Formula I
wherein: -
R1 is —
O—
(CH2)t—
CH3, wherein t is 11 to 19;a is 2 to 4; B is hydrogen, —
CH3, or —
CH2OH,Z is and the symbol * indicates that -*CH2—
in Formula I is attached to Z via N* in Formula A or B,or a pharmaceutically acceptable salt thereof; optionally in a pharmaceutically acceptable carrier. - View Dependent Claims (12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)
or a pharmaceutically acceptable salt thereof.
-
Specification